Isak W. Tengesdal

1.8k total citations
15 papers, 732 citations indexed

About

Isak W. Tengesdal is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Isak W. Tengesdal has authored 15 papers receiving a total of 732 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 9 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Isak W. Tengesdal's work include Inflammasome and immune disorders (7 papers), Immune cells in cancer (4 papers) and Immune Cell Function and Interaction (3 papers). Isak W. Tengesdal is often cited by papers focused on Inflammasome and immune disorders (7 papers), Immune cells in cancer (4 papers) and Immune Cell Function and Interaction (3 papers). Isak W. Tengesdal collaborates with scholars based in United States, Netherlands and Italy. Isak W. Tengesdal's co-authors include Charles A. Dinarello, Carlo Marchetti, Leo A. B. Joosten, Nicholas E. Powers, Tania Azam, Viola Klück, Benjamin J. Swartzwelter, Dennis M. de Graaf, Kiki Schraa and Tim Jansen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Isak W. Tengesdal

14 papers receiving 717 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Isak W. Tengesdal United States	12	422	303	155	92	83	15	732
Marjolein Garsen Netherlands	10	313 0.7×	201 0.7×	210 1.4×	73 0.8×	44 0.5×	11	829
Mianjing Zhou China	12	370 0.9×	418 1.4×	155 1.0×	71 0.8×	65 0.8×	17	794
Carolina Lavoz Spain	15	352 0.8×	181 0.6×	171 1.1×	98 1.1×	50 0.6×	26	738
Bihua Xu China	11	237 0.6×	219 0.7×	159 1.0×	52 0.6×	38 0.5×	14	588
Miriam C. Banas Germany	14	203 0.5×	242 0.8×	281 1.8×	178 1.9×	43 0.5×	32	807
Roman Günthner Germany	14	204 0.5×	231 0.8×	139 0.9×	38 0.4×	43 0.5×	32	601
Nithya Krishnan United States	16	232 0.5×	124 0.4×	140 0.9×	149 1.6×	107 1.3×	43	695
Chaohuan Guo China	16	568 1.3×	580 1.9×	198 1.3×	97 1.1×	84 1.0×	20	1.1k
Koei Yamada Japan	10	168 0.4×	257 0.8×	139 0.9×	66 0.7×	46 0.6×	10	630
Qingmiao Lu China	11	319 0.8×	187 0.6×	170 1.1×	75 0.8×	40 0.5×	15	682

Countries citing papers authored by Isak W. Tengesdal

Since Specialization

Citations

This map shows the geographic impact of Isak W. Tengesdal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isak W. Tengesdal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isak W. Tengesdal more than expected).

Fields of papers citing papers by Isak W. Tengesdal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isak W. Tengesdal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isak W. Tengesdal. The network helps show where Isak W. Tengesdal may publish in the future.

Co-authorship network of co-authors of Isak W. Tengesdal

This figure shows the co-authorship network connecting the top 25 collaborators of Isak W. Tengesdal. A scholar is included among the top collaborators of Isak W. Tengesdal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isak W. Tengesdal. Isak W. Tengesdal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Tengesdal, Isak W., et al.. (2024). Screening NLRP3 drug candidates in clinical development: lessons from existing and emerging technologies. Frontiers in Immunology. 15. 1422249–1422249. 12 indexed citations

Dinarello, Alberto, Taylor Mills, Isak W. Tengesdal, et al.. (2023). Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions. Cells. 12(2). 294–294. 6 indexed citations

Tengesdal, Isak W., Taylor Mills, Alan M. Elder, et al.. (2023). Metabolic Alterations Associated with Loss of TET2 Potentiates Inflammation in Myeloid Cells Driving Breast Cancer Progression. Blood. 142(Supplement 1). 2536–2536.

Tengesdal, Isak W., Charles A. Dinarello, & Carlo Marchetti. (2023). NLRP3 and cancer: Pathogenesis and therapeutic opportunities. Pharmacology & Therapeutics. 251. 108545–108545. 22 indexed citations

Graaf, Dennis M. de, Ruth X. Wang, Jesús Amo‐Aparicio, et al.. (2022). IL-38 Gene Deletion Worsens Murine Colitis. Frontiers in Immunology. 13. 840719–840719. 12 indexed citations

Tengesdal, Isak W., Suzhao Li, Nicholas E. Powers, et al.. (2022). Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers. Pharmaceuticals. 15(5). 574–574. 20 indexed citations

Tengesdal, Isak W., Alberto Dinarello, Nicholas E. Powers, et al.. (2021). Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. Frontiers in Immunology. 12. 661323–661323. 74 indexed citations

Ferrero, Elisabetta, Antonello Villa, Davide Stefanoni, et al.. (2021). Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis. Lara D. Veeken. 61(4). e93–e96. 1 indexed citations

Klück, Viola, Tim Jansen, M. Janssen, et al.. (2020). Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. The Lancet Rheumatology. 2(5). e270–e280. 197 indexed citations

10.

Li, Suzhao, Jesús Amo‐Aparicio, C. Preston Neff, et al.. (2019). Role for nuclear interleukin-37 in the suppression of innate immunity. Proceedings of the National Academy of Sciences. 116(10). 4456–4461. 48 indexed citations

11.

Marchetti, Carlo, Benjamin J. Swartzwelter, Marije I. Koenders, et al.. (2018). NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Research & Therapy. 20(1). 169–169. 134 indexed citations

12.

Ballak, Dov B., Suzhao Li, Giulio Cavalli, et al.. (2018). Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. Journal of Biological Chemistry. 293(37). 14224–14236. 44 indexed citations

13.

Tengesdal, Isak W., David Kitzenberg, Suzhao Li, et al.. (2018). The selective ROCK2 inhibitor KD025 reduces IL‐17 secretion in human peripheral blood mononuclear cells independent of IL‐1 and IL‐6. European Journal of Immunology. 48(10). 1679–1686. 17 indexed citations

14.

Cavalli, Giulio, Masahiro Hayashi, Ying Jin, et al.. (2016). MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proceedings of the National Academy of Sciences. 113(5). 1363–1368. 72 indexed citations

15.

Nowak, Kristen L., Michel Chonchol, T. Alp İkizler, et al.. (2016). IL-1 Inhibition and Vascular Function in CKD. Journal of the American Society of Nephrology. 28(3). 971–980. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact